

CONTENTS	PAGE NO.
List of Abbreviations	i
List of Figures	ii-iii
List of Tables	iv
Preface	v-vi
1. INTRODUCTION	
1.1. Drug Design, Discovery, and Development	1
1.2. Epilepsy: An Overview	4
1.3. GABA Hypothesis & Epilepsy	10
1.3.1. GABA Synthesis and Metabolism	11
1.3.2. GABA Receptors	12
1.3.3. GABA Transporters	13
1.4. Piperidine 3-Carboxylic Acid (Nipecotic Acid)	15
2. REVIEW OF LITERATURE	
2.1. Nipecotic Acid: An <i>In Vitro</i> GABA Reuptake Inhibitor	19
2.2. Piperidine-3-Carboxylic Acid Derivatives as Anticonvulsants	20
2.3. Naphthalene Derivatives as Anticonvulsants	30
3. RATIONAL, OBJECTIVE AND PLAN OF WORK	
3.1. Rationale & Objective	35
3.2. Plan of Work	36
3.2.1. Synthesis	36
3.2.2. Characterization of the Synthesized Compounds (Series 1 and 2)	37
3.2.3. Biological Evaluation of Series 1	37
3.2.4. Biological Evaluation of Series 2	37
3.2.5. Computational Studies of the Selected Leads from Series 1 & 2	38
4. EXPERIMENTAL	
4.1. Chemistry	39
4.1.1. Chemicals and Reagents	39
4.1.2. Series 1	39
4.1.2.1. <i>Method of Preparation</i>	39
4.1.2.2. <i>Reaction Mechanism for Series 1</i>	41
4.1.3. Series 2	41
4.1.3.1. <i>Method of Preparation</i>	41
4.1.3.2. <i>Reaction Mechanism for Series 2</i>	44

4.1.4. Characterization	44
4.1.4.1. Physicochemical Characterization	45
4.1.4.2. Spectral Characterization and Elemental Analysis	46
4.2. Biological Activity of Series 1	47
4.2.1. Animals	47
4.2.2. Drug Administration	48
4.2.3. <i>In Vivo</i> Anti-convulsant Activity	48
4.2.3.1. <i>sc-PTZ</i> Induced Seizures in Mice.....	48
4.2.3.2. Pilocarpine Induced Seizures in Mice	48
4.2.3.3. DMCM Induced Seizures in Mice	49
4.2.4. Rota-rod Performance Test in Mice.....	49
4.2.5. MTT Assay on Neuroblastoma Cell Line (SH-SY5Y).....	49
4.2.6. Repeated dose toxicity studies:.....	50
4.2.7. <i>In Vitro</i> PAMPA-BBB Assay	51
4.3. Biological Activity of Series 2	51
4.4. Statistical Analysis	52
4.5. Computational Studies.....	52
4.5.1. Homology Modelling of GAT-1	52
4.5.2. Molecular Docking Studies.....	53
4.5.3. Molecular Dynamics (MD) Simulations.....	54
4.5.4. Prediction of drug likeliness and <i>in silico</i> ADME properties.....	54
5. RESULTS AND DISCUSSION	
5A. SERIES 1	56
5.A.1. Chemistry	56
5.A.1.1. Physicochemical Characterization	56
5.A.1.2. Spectral Characterization and Elemental Analysis	57
5.A.2. Biological Activity.....	65
5.A.2.1. <i>In Vivo</i> Anti-convulsant Activity	65
5.A.2.1.1. <i>sc-PTZ</i> Induced Seizures in Mice	65
5.A.2.1.2. Pilocarpine-induced seizures in mice.....	67
5.A.2.1.3. DMCM induced seizures in mice.....	68
5.A.2.2. Rota-rod Performance Test in Mice.....	69
5.A.2.3. Cell viability and neurotoxicity (MTT Assay).....	69
5.A.2.4. Repeated dose toxicity studies	70

5.A.2.5. <i>In Vitro</i> PAMPA-BBB Assay	73
5.A.3. Computational Studies	74
5.A.3.1. Homology modeling of GAT-1.....	74
5.A.3.3. Molecular Dynamics	81
5.A.3.4. Estimation of “Drug-Like” Properties	84
5.B. SERIES 2	86
5.B.1. Chemistry	86
5.B.1.1. Physicochemical Characterization	86
5.B.1.2. Spectral Characterization and Elemental Analysis	88
5.B.2. Biological Activity	100
5.B.2.1. <i>In vitro</i> PAMPA-BBB assay	100
5.B.2.2. <i>In Vivo</i> Anti-convulsant Activity	102
5.B.2.2.1. <i>sc-PTZ Induced Seizures in Mice</i>	102
5.B.2.2.2. <i>DMCM Induced Seizures in Mice</i>	103
5.B.2.3. Rota-rod Performance Test in Mice	104
5.B.2.2. Cell viability and neurotoxicity (MTT Assay).....	105
5.B.2.3. Repeated dose toxicity studies	105
5.B.3. Computational Studies	107
5.B.3.1. Homology modeling of GAT-1.....	107
5.B.3.2. Molecular Docking Studies	107
5.B.3.3. Molecular Dynamics	112
5.B.3.4. Estimation of “Drug-Like” Properties.....	114
6. SUMMARY AND CONCLUSION	116
7. REFERENCES	121
8. APPENDIX	140